Geode Capital Management LLC raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 0.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,771,831 shares of the company's stock after buying an additional 26,727 shares during the quarter. Geode Capital Management LLC owned about 1.07% of Roivant Sciences worth $91,968,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC boosted its stake in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after purchasing an additional 1,288 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after buying an additional 1,507 shares during the period. Blue Trust Inc. grew its holdings in shares of Roivant Sciences by 550.1% during the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock worth $91,000 after buying an additional 6,667 shares in the last quarter. HighTower Advisors LLC acquired a new stake in Roivant Sciences in the 4th quarter valued at approximately $121,000. Finally, Avantax Advisory Services Inc. bought a new stake in Roivant Sciences in the 4th quarter valued at approximately $127,000. Institutional investors and hedge funds own 64.76% of the company's stock.
Analyst Ratings Changes
ROIV has been the topic of a number of recent research reports. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th.
View Our Latest Report on ROIV
Roivant Sciences Trading Down 1.9 %
Shares of Roivant Sciences stock traded down $0.19 on Tuesday, reaching $10.00. 3,292,231 shares of the company were exchanged, compared to its average volume of 5,397,595. The company has a market capitalization of $7.14 billion, a price-to-earnings ratio of -66.66 and a beta of 1.25. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06. The company has a 50-day moving average of $10.38 and a 200 day moving average of $11.21.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Insider Activity at Roivant Sciences
In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00. Following the transaction, the chief operating officer now directly owns 732,294 shares in the company, valued at $8,260,276.32. The trade was a 12.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now directly owns 163,264 shares in the company, valued at $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,395,541 shares of company stock worth $15,028,538. Insiders own 7.90% of the company's stock.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
See Also
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
